Mesoblast Share Price and Company Fundamentals
Last traded: Today at 3:28 AM
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
3.67
Dividend yield
-
Beta
0.90
Market cap
$3.18B
Enterprise value
$3.16B
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Full time employees | 81 |
| Website | https://www.mesoblast.com |
| Mailing address | 55 Collins Street Level 38 Melbourne VIC 3000 Australia |
| Phone / Fax | 61 3 9639 6036 / 61 3 9639 6030 |
Dividends
More: Mesoblast Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Mesoblast paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.MSB dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Mesoblast.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director | 68 | |
| Dr. Eric A. Rose M.D. | Chief Medical Officer & Executive Director | 74 | |
| Mr. James Michael O'Brien | Chief Financial Officer | 59 | |
| Mr. Peter T. Howard B.Sc., L.L.B. | General Counsel & Corporate Executive | 57 | |
| Dr. Paul J. Simmons BSc, Ph.D. | Scientific Advisor to the Chief Executive Officer | 66 | |
| Ms. Geraldine Storton B.Sc., M.B.A., MMS | Head of Regulatory Affairs & Quality Management | ||
| Mr. Justin Horst B.S. | Head of Manufacturing | ||
| Dr. Fiona See Ph.D. | Senior VP & Head of Translational Research | ||
| Mr. Marcelo Santoro | Chief Commercial Officer | ||
| Ms. Niva Sivakumar B.Com., L.L.B. | Joint Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-302.37%
Return on assets
-5.37%
Return on equity
-18.95%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Mesoblast is 3.18B and its enterprise value is 3.16B. The enterprise value to revenue ratio of MSB is 183.55. The enterprise value to EBITDA ratio of MSB is -54.25.
The MSB's stocks Beta value is 0.90 making it 10% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Mesoblast (MSB)
Mesoblast (ASX:MSB) Frequently Asked Questions
1. What is Mesoblast's Stock Symbol?
Mesoblast trades on ASX under the ticker symbol "MSB".
2. What is Mesoblast's stock price today?
One share of MSB stock can currently be purchased for approximately $2.465.
3. How can I contact Mesoblast?
Mesoblast's mailing address is 55 Collins Street Level 38 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9639 6036.
4. What is Mesoblast's official website?
The official website of Mesoblast is https://www.mesoblast.com.